BibTex RIS Kaynak Göster

Herpes Zoster Oftalmikus Tedavisinde Antiviral İlaç Zamanlaması

Yıl 2014, Cilt: 5 Sayı: 11, - , 01.11.2014

Yakup Aksoy Yusuf Emrah Eyi

Anahtar Kelimeler

-

Kaynakça

  • Sayhan M B, Sezenler E, Nalbur I H, Yağcı G, Gezer E. Herpes Zoster Oftalmikus JAEMCR 2012; 3: 74-6. [CrossRef]
  • Catron T, Hern HG. Herpes Zoster Ophthalmicus. West J Emerg Med 2008; 9: 174-6.
  • Heymann AD, Chodick G, Karpati T, Kamer L, Kremer E, Green M.S, et al. Diabetes as a risk factor for herpes zoster infection: results of a population-based study in Israel. Infection 2008; 36: 226-30. [CrossRef]
  • Gross G, Schöfer H, Wassilew S, Friese K, Timm A, Guthoff R, et al. Herpes zoster guideline of the German Dermatology Society (DDG). J Clin Virol 2003; 26: 277-89; discussion 291-3. [CrossRef]
  • Schmader K, Gnann J.W. Watson C.P. The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. J Infect Dis 2008;197: 207-15. [CrossRef]
  • Galluzzi KE. Managing herpes zoster and postherpetic neuralgia. J Am Osteopath Assoc 2009; 109: 7-12.

The Timing of Antiviral Drugs in the Treatment of Herpes Zoster Ophthalmicus

Yıl 2014, Cilt: 5 Sayı: 11, - , 01.11.2014

Yakup Aksoy Yusuf Emrah Eyi

Anahtar Kelimeler

-

Kaynakça

  • Sayhan M B, Sezenler E, Nalbur I H, Yağcı G, Gezer E. Herpes Zoster Oftalmikus JAEMCR 2012; 3: 74-6. [CrossRef]
  • Catron T, Hern HG. Herpes Zoster Ophthalmicus. West J Emerg Med 2008; 9: 174-6.
  • Heymann AD, Chodick G, Karpati T, Kamer L, Kremer E, Green M.S, et al. Diabetes as a risk factor for herpes zoster infection: results of a population-based study in Israel. Infection 2008; 36: 226-30. [CrossRef]
  • Gross G, Schöfer H, Wassilew S, Friese K, Timm A, Guthoff R, et al. Herpes zoster guideline of the German Dermatology Society (DDG). J Clin Virol 2003; 26: 277-89; discussion 291-3. [CrossRef]
  • Schmader K, Gnann J.W. Watson C.P. The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. J Infect Dis 2008;197: 207-15. [CrossRef]
  • Galluzzi KE. Managing herpes zoster and postherpetic neuralgia. J Am Osteopath Assoc 2009; 109: 7-12.
Toplam 6 adet kaynakça vardır.

Ayrıntılar

Diğer ID JA64EG75EF
Bölüm Editöre Mektup
Yazarlar

Yakup Aksoy Bu kişi benim

Yusuf Emrah Eyi Bu kişi benim

Yayımlanma Tarihi 1 Kasım 2014
Gönderilme Tarihi 1 Kasım 2014
Yayımlandığı Sayı Yıl 2014 Cilt: 5 Sayı: 11

Kaynak Göster

APA Aksoy, Y., & Eyi, Y. E. (2014). The Timing of Antiviral Drugs in the Treatment of Herpes Zoster Ophthalmicus. Journal of Emergency Medicine Case Reports, 5(11).
AMA Aksoy Y, Eyi YE. The Timing of Antiviral Drugs in the Treatment of Herpes Zoster Ophthalmicus. Journal of Emergency Medicine Case Reports. Kasım 2014;5(11).
Chicago Aksoy, Yakup, ve Yusuf Emrah Eyi. “The Timing of Antiviral Drugs in the Treatment of Herpes Zoster Ophthalmicus”. Journal of Emergency Medicine Case Reports 5, sy. 11 (Kasım 2014).
EndNote Aksoy Y, Eyi YE (01 Kasım 2014) The Timing of Antiviral Drugs in the Treatment of Herpes Zoster Ophthalmicus. Journal of Emergency Medicine Case Reports 5 11
IEEE Y. Aksoy ve Y. E. Eyi, “The Timing of Antiviral Drugs in the Treatment of Herpes Zoster Ophthalmicus”, Journal of Emergency Medicine Case Reports, c. 5, sy. 11, 2014.
ISNAD Aksoy, Yakup - Eyi, Yusuf Emrah. “The Timing of Antiviral Drugs in the Treatment of Herpes Zoster Ophthalmicus”. Journal of Emergency Medicine Case Reports 5/11 (Kasım 2014).
JAMA Aksoy Y, Eyi YE. The Timing of Antiviral Drugs in the Treatment of Herpes Zoster Ophthalmicus. Journal of Emergency Medicine Case Reports. 2014;5.
MLA Aksoy, Yakup ve Yusuf Emrah Eyi. “The Timing of Antiviral Drugs in the Treatment of Herpes Zoster Ophthalmicus”. Journal of Emergency Medicine Case Reports, c. 5, sy. 11, 2014.
Vancouver Aksoy Y, Eyi YE. The Timing of Antiviral Drugs in the Treatment of Herpes Zoster Ophthalmicus. Journal of Emergency Medicine Case Reports. 2014;5(11).